Dr Lam is recognized globally for expertise in heart failure with preserved ejection fraction. She is a world-renown clinical trialist, with her work as part of the global steering committees of PARAGON and EMPEROR-Preserved trials contribution to the first approved treatments for HFpEF to date. She was appointed to the 2021 European Society of Cardiology Heart Failure Guidelines Task Force and has published >300 articles in journals including NEFM, JAMA, Lancet, Circulation and European Heart Journal; being recognized as Clarivate’s Highly cited Researcher 2021 in Clinical Medicine. She serves as Associate Editor for Circulation and European Journal of Heart Failure. In the field of MedTech, Dr. Lam is co-founder of Us2.ai, an award-winning startup dedicated to the automation of the fight against heart disease by applying artificial intelligence to echocardiography (ultrasound of the heart).
Session:
Competency & Capacity, 8 October 2022, 1030 - 1230hrsHow AI in Echocardiography can Improve Workflow and Enable Community-based Cardiac Screening
Return to Speakers >